Rivoceranib

Unassigned

New Medicines

Advanced gastric cancer or gastro-oesophageal junction cancer, that has progressed since last treatment with at least two prior lines of therapies

Information

New molecular entity
Elevar Therapeutics
Elevar Therapeutics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes

Category

A selective potent inhibitor of vascular endothelial growth factor receptor-2 (known as VEGFR2) which mediates the primary pathway for tumour-mediated angiogenesis
Gastric cancer is the second most common cause of cancer-related death in the world. It is a difficult disease to cure, mainly because most patients present with advanced disease. Around 6,700 people are diagnosed with stomach cancer in the UK each year [2014-16 data]. Around 20% of gastric cancers are HER2 positive. The number of people in the UK diagnosed with stomach cancer has been falling over the last 10 years [1-3].
Advanced gastric cancer or gastro-oesophageal junction cancer, that has progressed since last treatment with at least two prior lines of therapies
Oral

Further information

Yes
To be confirmed

Evidence based evaluations